Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T Oct 19 | 2022Carvykti’s Revenue Increases to $55M; JNJ Expects Franchise to Generate $5B by 2025; Will Carvykti be Approved in 2L MM by Q3 2023? JNJ Q3 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Oct 18 | 2022The EC Grants Yescarta Marketing Authorization in 2L LBCLAccess Free Blast
Free
Posted in: CAR-T Oct 14 | 2022No Cell Therapy-Related Updates in October’s CHMP HighlightsAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 10 | 2022No Cell Therapy-Related Updates in October’s CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, CD19 Oct 07 | 2022Allogene Initiates ALLO-501A’s Pivotal Ph2 TrialAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, TCR Oct 06 | 2022Could Carvykti be Approved in 2L MM by 2023? Legend Introduces New γδ CAR-T Program; Updates to Solid Tumor Programs; Thoughts on Legend’s R&D Day 2022Access Free Blast
Free
Posted in: Autologous, CAR-T Oct 04 | 2022BMS to Leverage Autolus's Safety SwitchAccess Free Blast
Free
Posted in: Autologous, CAR-T, TCR Sep 30 | 2022TCR2 Tx Completes Gavo-Cel’s Ph1 Trial; Dosing Started in Gavo-cel’s Pivotal Ph2 Study; Gilead’s KITE-222 Receives Orphan Drug DesignationAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Sep 28 | 2022Carvykti Approved in Japan for ≥4L r/r MMAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Sep 27 | 2022Could Novartis Deprioritize T-Charge? Novartis to Focus Exclusively on Innovative Medicines; Thoughts on Novartis Meet the Management Investor Event 2022Access Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Sep 23 | 2022Servier Discontinues Partnership with AllogeneAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Sep 23 | 2022Could JNJ Change the Treatment Paradigm in MM? Spotlight on JNJ’s MM FranchiseAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Sep 16 | 2022CHMP Adopts Positive Opinion for Yescarta; Breyanzi Absent from September’s CHMP HighlightsAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19 Sep 14 | 2022Gilead Messages on Solid Tumor Capabilities and Novel Manufacturing Methods; Gilead’s (Kite) ESMO 2022 Industry SymposiumAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19, Topics Sep 13 | 2022New Tecartus Ph2 Trial (ZUMA-25) for R/R Rare B-cell MalignanciesAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, Topics Sep 13 | 2022Updated Results from BioNTech’s BNT211; Triumvira’s TAC01-HER2 Clinical Safety and Efficacy Data; Dosing Levels of ICT’s GCC19CART; ESMO 2022 Presentations AnalysisAccess Free Blast
Free
Posted in: Autologous, TCR, Topics Sep 12 | 2022Clinical Updates from ADP-A2M4CD8’s SURPASS Study; Adaptimmune to Evaluate Multiple Combinations in the SURPASS Program; Adaptimmune’s ESMO 2022 Investor EventAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Sep 12 | 2022Type II Variations for Yescarta and Breyanzi Listed in September’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Sep 09 | 2022UPDATED: Indications Table for BCMA and CD19 CAR-Ts US Approvals and SubmissionsAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Sep 07 | 2022The EC Grants Tecartus Marketing Authorization for R/R Adult ALLAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.